While this finding may be due to the limited number of HER2+ cancers in our tumour sample, it is in broad agreement with findings from previous reports [19, 20] and may be attributed to the higher proliferation rates found in HER2+ vs HER2- cancers [21]. Here, ERBB2 is linked to neoplasm.